FDA Expands Alpha Tau Cancer Trial; WHO Classifies Tumors
What happened
The U.S. Food and Drug Administration approved an Investigational Device Exemption supplement for Alpha Tau Medical Ltd.'s REGAIN trial. This approval expands the trial from 10 to 20 patients and includes additional study endpoints. Separately, the World Health Organization classified IDH-mutant grade 4 tumors.
From manilatimes.net
Why it matters
The expanded REGAIN trial aims to gather more information on using Alpha DaRT to treat recurrent glioblastoma. The additional data generated by the trial could support market submission requirements for Alpha DaRT in patients with this condition.
From manilatimes.net
Who's involved
- FDARegulatory agency that approved the IDE supplement for the Alpha Tau trial.
- World Health OrganizationInternational health body that classified IDH-mutant grade 4 tumors.
- Ohio State UniversityAcademic center participating in the clinical trial.
- Joshua PalmerPrincipal investigator of the REGAIN study.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Ohio State UniversitySpeculative
Ohio State University could generate research revenue from increased clinical trial enrollment and scope.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Expanded Alpha Tau trial could boost Ohio State University Hospital's research capacityOhio State University Hospital may see increased clinical volume from expanded cancer trialLikely
- IARC may adjust cancer research guidelines after WHO's new tumor classificationIARC may need to adjust research guidelines following WHO's tumor classificationPossible
- Expanded Alpha Tau trial may boost Ohio State University research scopeOhio State University may see increased research scope from expanded Alpha Tau trialPossible
Keep exploring
The entities involved
- FDA
-
World Health Organization
United Nations agency concerned with international public health